|
CEP192 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.24979999999819E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.702800000009E-05 |
| Normal-vs-Stage2 |
8.2925000000067E-05 |
| Normal-vs-Stage3 |
4.45419999994812E-06 |
| Normal-vs-Stage4 |
2.13969999999231E-05 |
| Stage1-vs-Stage2 |
2.539800E-01 |
| Stage1-vs-Stage3 |
1.239610E-01 |
| Stage1-vs-Stage4 |
2.333600E-01 |
| Stage2-vs-Stage3 |
9.936800E-01 |
| Stage2-vs-Stage4 |
8.321000E-01 |
| Stage3-vs-Stage4 |
8.051600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.18839999999565E-05 |
| Normal-vs-AfricanAmerican |
1.520110E-03 |
| Normal-vs-Asian |
1.905670E-02 |
| Caucasian-vs-AfricanAmerican |
7.071200E-01 |
| Caucasian-vs-Asian |
3.497000E-01 |
| AfricanAmerican-vs-Asian |
3.484000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62521999998999E-05 |
| Normal-vs-Female |
3.6560999999713E-06 |
| Male-vs-Female |
6.886600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.152800E-04 |
| Normal-vs-Age(41-60Yrs) |
3.75310000000351E-05 |
| Normal-vs-Age(61-80Yrs) |
6.6575000001734E-07 |
| Normal-vs-Age(81-100Yrs) |
1.954280E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.679800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.506300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.546600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.905420E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.959200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.235400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.741580E-03 |
| Classical-VS-Follicular |
3.261100E-03 |
| Classical-VS-Other |
9.139600E-01 |
| Classical-VS-Normal |
1.542000E-03 |
| Tall-VS-Follicular |
7.590400E-01 |
| Tall-VS-Other |
3.655000E-01 |
| Tall-VS-Normal |
3.91890000006612E-07 |
| Follicular-VS-Other |
4.282000E-01 |
| Follicular-VS-Normal |
3.47820000001775E-06 |
| Other-VS-Normal |
1.466440E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.63299999984035E-07 |
| Normal-vs-N1 |
3.364100E-04 |
| N0-vs-N1 |
7.703600E-01 |
|
|
